- Home
- PLUR
PLUR
Pluri Inc.
as 01-17-2025 4:00pm EST
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.
| Founded: | 2001 | Country: | Israel |
| Employees: | N/A | City: | HAIFA |
| Market Cap: | 27.7M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 10.3K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.10 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.07 - $8.48 | Next Earning Date: | 02-10-2025 |
| Revenue: | $598,000 | Revenue Growth: | 135.43% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Pluri Inc. News
PLUR Breaking Stock News: Dive into PLUR Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease
GlobeNewswire
a month ago
Pluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025
ACCESSWIRE
2 months ago
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing
GlobeNewswire
2 months ago
Pluri Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear Threat Concerns
Simply Wall St.
2 months ago
Pluri First Quarter 2025 Earnings: US$1.08 loss per share (vs US$0.96 loss in 1Q 2024)
Associated Press Finance
2 months ago
Pluri: Fiscal Q1 Earnings Snapshot
ACCESSWIRE
2 months ago
Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event
PR Newswire
2 months ago
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing
Compare PLUR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PLUR Pluri Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.